The impact of recalled elementary school height and weight on later weight concerns.

Although overweight children and adolescents experience a number of immediate difficulties, little research has investigated the long-term psychological consequences for individuals who were overweight as children or adolescents despite their weight status as young adults. The goal of this study was to examine the relations between individuals' retrospective reports of their weight and height during elementary and high school, and their past and current weight concerns. It was expected that individuals who recall being overweight as a child or adolescent would have more weight concerns than their peers who recall being normal weight, even after controlling for current body size. Participants were 174 females and 61 males, ranging in age from 18-20 (M=18.66 yr, SD=0.63). For females, perceived elementary school weight in comparison to their peers significantly predicted current weight concerns, p<0.05. For males, perceived elementary school height in comparison to their peers significantly predicted a history of weight concerns, p<0.05. Retrospective height and weight in high school did not impact current weight concerns for either males or females.

Onycholysis associated with weekly administration of paclitaxel.

OBJECTIVE: To report an unusual reaction associated with weekly administration of paclitaxel. CASE SUMMARIES: Onycholysis was seen in four women with recurrent ovarian cancer being treated with low-dose, weekly paclitaxel. Two of the patients had previously received higher doses of paclitaxel on an every-three-week schedule without similar reactions. Onycholysis developed between weeks 10-13 of treatment in three of the patients. In the fourth patient, it developed shortly after initiation of weekly paclitaxel. None of the reactions required dose adjustments or discontinuation of therapy. Direct toxicity to the nail bed or inhibition of angiogenesis are possible mechanisms for this reaction. DISCUSSION: Onycholysis, separation of the nail from the nail bed, is an infrequent adverse effect of drug therapy. Antineoplastic drugs have previously been reported to cause onycholysis, pigmentation, bands, thickening or thinning of the nail bed, and nail shedding. Nail changes with the taxanes, primarily docetaxel, are reported in up to 30-40% of patients. Paclitaxel is not commonly associated with dermatologic reactions, although localized skin reactions and tissue necrosis have been reported. Nail changes, pigmentation or discoloration of the nail bed, occur in 2% of patients receiving paclitaxel. CONCLUSIONS: Onycholysis is an uncommon reaction that may occur in some patients receiving weekly, low-dose paclitaxel therapy. The reaction is not life-threatening and does not warrant discontinuation of therapy. However, clinicians should be aware of the possibility of this effect and be prepared to advise patients who develop signs of nail changes.